Streetbeat News

Regulatory

UTME

UTime has been granted a 180-day extension by Nasdaq to meet the minimum bid price rule, allowing the company more time to comply with stock listing requirements.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 6:51 am

IVBIY

Innovent Biologics, Inc. (IVBIY) and AnHeart Therapeutics announced the acceptance of a second New Drug Application (NDA) by China's NMPA for taletrectinib, a treatment for ROS1-positive lung cancer. This marks a significant step in providing a new first-line treatment option for patients with this type of cancer.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 6:15 am

AMD

NVDA

Advanced Micro Devices Inc. (AMD) faces challenges in exporting a China-specific AI chip due to U.S. Department of Commerce restrictions. Despite designing the chip to comply with U.S. export regulations by lowering its performance, officials deemed it too powerful, requiring a license for sale. This is part of broader U.S. efforts to limit China's access to advanced semiconductors, affecting companies like AMD and Nvidia Corporation (NVDA). Meanwhile, Chinese firms like SMIC are advancing in chip development, and Nvidia aims to dominate the Chinese market despite restrictions.

Portfolio Pulse from Ananya Gairola

March 05, 2024 | 2:51 am

AMD

FXI

SPY

Bloomberg reports that AMD faces a US regulatory obstacle in selling its AI chip specifically designed for the Chinese market. This development could impact AMD's business operations in China and potentially affect its stock price.

Portfolio Pulse from Charles Gross

March 05, 2024 | 1:45 am

EYEN

Formosa Pharmaceuticals and AimMax Therapeutics have received FDA approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, aimed at treating post-operative inflammation and pain following ocular surgery. They plan to collaborate with Eyenovia, Inc. for U.S. commercialization, while also seeking to expand into additional territories and advance their early-stage pipeline.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 10:59 pm

NTDOY

Nintendo ADR (OTC:NTDOY) has settled a legal dispute with Tropic Haze LLC for $2.4 million over the Yuzu emulator, which allowed unauthorized play of Nintendo games. Tropic Haze will cease all Yuzu-related activities and transfer the domain to Nintendo. This settlement could impact the future of Switch emulation and sets a precedent regarding copyright laws and emulation. The lawsuit highlighted Yuzu's role in enabling piracy, notably over a million pre-release plays of Legend of Zelda: Tears of the Kingdom.

Portfolio Pulse from Franca Quarneti

March 04, 2024 | 10:22 pm

BYDDY

F

LI

NIO

TSLA

XPEV

Chinese EV makers, led by BYD Company ADR, are outpacing their global counterparts, including Tesla, in production speed and innovation. This has raised concerns among U.S. automakers and government officials about the potential market impact and national security threats posed by Chinese EVs. Despite facing a 25% tariff barrier, Chinese companies like NIO Inc are planning to enter the U.S. market by 2025. The U.S. is responding with investments in EV infrastructure and probes into the security risks of Chinese EV technology.

Portfolio Pulse from Natan Ponieman

March 04, 2024 | 10:05 pm

ENB

Enbridge Inc. (NYSE:ENB) has received approval from the Canada Energy Regulator for its Mainline Tolling settlement, effective until December 31, 2028. This settlement establishes tariffs for crude oil and liquids shipments across North America, promising competitive service for customers, attractive returns for Enbridge, and a long-term energy source for the market. The agreement, unanimously approved by the industry, was retroactively effective from July 1, 2021.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:41 pm

WISH

ContextLogic announced it has stopped providing guidance due to a pending transaction, indicating a significant corporate action that could affect its future operations and financial outlook.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:16 pm

STXS

Stereotaxis, Inc. has announced that it has recently made regulatory submissions in both Europe and the US for its MAGiC Catheter, signaling a significant step towards the commercialization of this new technology.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 9:08 pm